HMPL-A580 for advanced or metastatic solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor that has spread or cannot be removed.
- You must have at least one tumor that can be measured on a scan.
- Your cancer must be confirmed by a biopsy (tissue sample).
- You must be able to care for yourself (ECOG score of 0 or 1).
- You must not have type 1 diabetes or uncontrolled type 2 diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
This trial tests a new drug called PLT012 for people with advanced solid tumors. It is the first study in humans, so doctors will see if the drug is safe and how the body handles it.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests an experimental drug called HMPL-A830 for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug can shrink tumors or slow their growth.
This early-phase trial tests a new investigational drug (HMPL-415S1) in people with advanced solid tumors that have limited treatment options. It aims to see how the drug is tolerated and whether it can shrink tumors, especially in cases with KRAS-pathway changes.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.